Search Results
Oct 13, 2025, 09:00 ET Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced
More news about: Avidity Biosciences, Inc.
Oct 13, 2025, 06:00 ET ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
developing innovative therapies for patients with serious neurogenetic diseases worldwide. ReviR was founded in 2021 by leaders in computational biology, RNA biology, and drug discovery, with the aim to create disease-modifying therapies that are highly specific, efficacious, and safe. ReviR's lead candidate,
More news about: ReviR Therapeutics
Oct 09, 2025, 10:00 ET FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine
FYR utilizes AI-enabled multiomic insights through its EV-Omics (EVO) platform to unravel the complexities of disease mechanisms. By identifying RNA and protein biomarkers from EVs in blood, FYR uncovers novel disease insights, builds robust datasets to enhance clinical trials and delivers actionable
More news about: CIQ
Oct 09, 2025, 07:00 ET Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
developed a new generation of nanopore-based sensing technology that is currently used for information-rich, rapid, accessible and affordable DNA and RNA analysis. The platform is also being developed for the analysis of proteins and metabolites. The technology is being used in more than 125 countries
More news about: Bio-Techne Corporation
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
Oct. 9, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following investor and industry events:
More news about: ARTHEx Biotech
Oct 08, 2025, 17:31 ET Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight
therapy designed to treat hereditary transthyretin-mediated (hATTR) amyloidosis by directly targeting the root cause of the disease. It uses a guide RNA to direct the Cas9 enzyme to the TTR gene in liver cells, where Cas9 introduces a double-stranded break in the DNA.
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
from $58 billion in 2024 to $120 billion by 2030, according to Mordor Intelligence[4], while over 120 clinical trials are testing RNA-based cancer vaccines that have already reduced melanoma recurrence by 44%[5]. GT Biopharma,
More news about: Equity Insider
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
technologies TTX-siPDL1, siRNA-based modulator of PD-L1 TTX-RIGA, RNA-based agonist of RIG-I TTX-siMYC, RNA-based inhibitor of c-MYC About the Acquisition and
More news about: TransCode Therapeutics, Inc.
Oct 08, 2025, 08:00 ET CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
Mass., Oct. 8, 2025 /PRNewswire/ -- CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO) and Chief Business Officer
More news about: CREATE Medicines, Inc.
Oct 07, 2025, 18:20 ET Klotho Neurosciences Announces Expiration of Letter of Intent
Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical
More news about: Klotho Neurosciences, Inc.
Oct 07, 2025, 14:11 ET Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay
tumor types. Built on Roche's AVENIO NGS platform and leveraging FoundationOne's bioinformatics pipeline, the assay interrogates 335 DNA genes and 72 RNA genes to identify single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), and structural variants (SVs), including
More news about: Circulogene
Oct 07, 2025, 11:20 ET Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
Biogen Inc. Biogen dominates the ASO space with Spinraza® and is advancing ALS-specific RNA-based therapies. Its 2025 approval strengthens its neurology franchise. Sarepta Therapeutics
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
accelerating growth. RNA-based Therapies, valued at US$ 26 billion in 2024, are gaining rapid adoption following the success of mRNA vaccines. Companies such as Sarepta and Alnylam are expanding RNA-based pipelines in neuromuscular and metabolic disorders.
More news about: DataM Intelligence 4 Market Research LLP
Oct 06, 2025, 09:00 ET Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
DIEGO, Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced
More news about: Avidity Biosciences, Inc.
Oct 06, 2025, 09:00 ET NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD. About PARADIGM PARADIGM is a prospective,
More news about: NeuroSense
Oct 06, 2025, 08:30 ET Novel Long RNA Manufacturing Approaches for Advancing RNA Therapeutics, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how innovative long RNA manufacturing approaches can drive the development of next-generation RNA medicines. Attendees will understand the limitations of current methods (chemical synthesis and IVT) for long-chain RNA production and the challenges with base modifications.
More news about: Xtalks
Oct 06, 2025, 08:00 ET Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming
Flexible durability: Transient or stable CAR expression, with permanent integration via RNA-based retrotransposon technology. Industry-leading RNA: Up to 8+ days of linear mRNA expression with no reactogenicity.
More news about: CREATE Medicines, Inc.
Oct 03, 2025, 05:58 ET Active Pharmaceutical Ingredients (API) Market to Surpass US$ 428.5 Billion by 2033 as Biotech APIs and Oncology Applications Lead Global Growth | DataM Intelligence
APIs are developed and supplied. The industry is also seeing accelerated adoption of biotech APIs, particularly monoclonal antibodies, peptides, and RNA-based molecules. Global supply chains are adjusting to post-pandemic resilience strategies, with leading players such as Pfizer,
More news about: DataM Intelligence 4 Market Research LLP
Oct 03, 2025, 05:00 ET Glioblastomas Affect Much More Than Just the Brain
could profoundly change its immune landscape. A Tilt Towards Inflammation Using single-cell RNA sequencing, the researchers found that glioblastoma had dramatically shifted the skull marrow's immune-cell balance in favor of pro-inflammatory myeloid
More news about: Montefiore Einstein Comprehensive Cancer Center
Oct 02, 2025, 07:40 ET Molecular Designs Submits Simplicity™DX Respiratory Panel for FDA 510(k) Clearance
without sacrificing accuracy or flexibility." The panel is a multiplex real-time RT-PCR assay that is designed to detect viral RNA in anterior nasal swabs. It includes two targets for SARS-CoV-2, one each for Influenza A and B, and two for RSV, alongside an internal control to validate
More news about: Molecular Designs
Oct 01, 2025, 09:01 ET Laguna Diagnostics Awarded Second U.S. Patent for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder, Expanding IP Portfolio in $3B Market
*Ribonucleic acid (RNA) is a polymeric molecule essential for most biological functions, either performing roles directly (non-coding RNA) or serving as the template for protein production (messenger RNA).
More news about: Laguna Diagnostics, LLC
Oct 01, 2025, 08:53 ET Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein Cargo to the Brain
The result is an advanced drug delivery system in a scalable, low-cost production platform that helps unlock the potential of protein therapeutics, RNA therapeutics, and small-molecule drugs. Contact: Kaelie Barnard | Dir. Marketing, Barson Corp.
More news about: Mercury Bio Inc.
Sep 30, 2025, 17:31 ET HPV-Positive Oropharyngeal Cancer Market Poised for Strong Growth by 2034, Driven by Rising Incidence and Treatment Innovation | DelveInsight
Broader adoption of molecular diagnostics and HPV testing The routine use of p16 immunohistochemistry, HPV DNA/RNA testing, and improved pathology workflows has increased detection and more reliably stratified patients as HPV-positive. Better diagnostic capture expands
More news about: DelveInsight Business Research, LLP
Sep 30, 2025, 10:45 ET Global Aircraft Insurance Market Poised for Steady Growth: Valued at USD 6.5 Billion in 2024, Expected to Reach USD 9.2 Billion by 2033: Market Research Intellect
Therapeutic Modality, Protein Therapeutic Modality, Peptide Therapeutic Modality, Endoglin Antibody Therapeutic Modality, Stem Cell Therapeutic Modality, Rna Therapeutic Modality, Other), By Geographic Scope, And Future Trends Forecast
More news about: Market Research Intellect
Sep 30, 2025, 09:30 ET Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics